Alnylam, Medtronic to Get Funding for Huntington's Disease Program
November 04, 2010
Alnylam, Medtronic to Get Funding for Huntington's Disease Program
Alnylam said that the non-profit CHDI Foundation has agreed to pay up to 50 percent of the costs of advancing a treatment for the disease up through an investigational new drug application filing.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Alnylam Steps Back from Huntington's Drug Deal, Sees Two Partnerships by Year-End
May 10, 2012 / Gene Silencing News - Alnylam Presents Clinical Data from Cholesterol Drug Trial, Animal Data from Huntington's Program
January 5, 2012 / Gene Silencing News - Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space
July 22, 2010 / Gene Silencing News - Alnylam, Medtronic Release Preclinical Data from Huntington's Disease Program
September 17, 2009 / Gene Silencing News - Lundbeck, UMMS to Collaborate on RNAi Therapeutic for Huntington's Disease
February 3, 2011 / Gene Silencing News